|
Dr. DeLuca-Flaherty has served as Executive Director, Project Management and Project Leader of the FVIIa/Hemphilia program at Catalyst. Dr. DeLuca-Flaherty joined Catalyst in June 2006 from Exelixis where she was most recently Senior Director of Development Project Management. In this capacity, she served on numerous project teams that spanned development stages pre-IND through Phase 3 clinical trials. In the role of Director of Research Operations, Dr. DeLuca-Flaherty played a central role in the transition of Exelixis from a platform technology to a fully integrated drug discovery/development company. Dr. DeLuca-Flaherty joined Exelixis as the company's first alliance manager in 1998. Prior to Exelixis, Dr. DeLuca-Flaherty led diverse research teams in the identification of novel protease inhibitors first at Sandoz Agro and later at Affymax, where she interacted with drug discovery teams from Glaxo Wellcome's sites in Research Triangle Park, Verona Italy, and Geneva Switzerland. Dr. DeLuca-Flaherty received her Ph.D. in Biochemistry from the University of Colorado and completed her post doctoral training in structural biology at Stanford University. | 